An increasing number of diseases are now recognized as being driven by inflammatory processes, and consequently involve various cells of the immune system. These cells include macrophages, microglial cells, T-cells, B-cells, monocytes and mast cells. Plexxikon is developing novel agents that target a number of these cells to address unmet medical needs in rheumatoid arthritis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD) and osteoporosis.

Rheumatoid Arthritis

Plexxikon is developing PLX3397, a novel, oral and highly selective kinase inhibitor that inhibits macrophages, osteoclasts and mast cells. These are all key drivers of a number of inflammatory diseases, including rheumatoid arthritis and multiple sclerosis, as well as certain cancers.

PLX3397 is currently in a Phase 1 clinical trial to test PLX3397 for initial safety, tolerability and pharmaceutical properties in cancer patients. An additional follow-on Phase 1b study is planned in patients with rheumatoid arthritis.

As demonstrated in preclinical studies, this compound is expected to reduce inflammation and bone erosion, as well as modulate the resultant bone pain.